JP2024506116A5 - - Google Patents
Info
- Publication number
- JP2024506116A5 JP2024506116A5 JP2023531615A JP2023531615A JP2024506116A5 JP 2024506116 A5 JP2024506116 A5 JP 2024506116A5 JP 2023531615 A JP2023531615 A JP 2023531615A JP 2023531615 A JP2023531615 A JP 2023531615A JP 2024506116 A5 JP2024506116 A5 JP 2024506116A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- cancer
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020132454 | 2020-11-27 | ||
| CNPCT/CN2020/132454 | 2020-11-27 | ||
| CNPCT/CN2021/081236 | 2021-03-17 | ||
| CN2021081236 | 2021-03-17 | ||
| PCT/CN2021/133429 WO2022111621A1 (en) | 2020-11-27 | 2021-11-26 | Aminoheteroaryl kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506116A JP2024506116A (ja) | 2024-02-09 |
| JP2024506116A5 true JP2024506116A5 (https=) | 2024-12-04 |
Family
ID=81753779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531615A Pending JP2024506116A (ja) | 2020-11-27 | 2021-11-26 | アミノヘテロアリールキナーゼ阻害剤 |
| JP2024531423A Pending JP2024541533A (ja) | 2020-11-27 | 2022-11-23 | アミノヘテロアリールキナーゼ阻害薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531423A Pending JP2024541533A (ja) | 2020-11-27 | 2022-11-23 | アミノヘテロアリールキナーゼ阻害薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240166635A1 (https=) |
| EP (2) | EP4251613A4 (https=) |
| JP (2) | JP2024506116A (https=) |
| KR (1) | KR20230127228A (https=) |
| CN (2) | CN116528869B (https=) |
| AU (3) | AU2021385745C1 (https=) |
| CA (2) | CA3202990A1 (https=) |
| IL (1) | IL303237A (https=) |
| MX (1) | MX2024006300A (https=) |
| WO (2) | WO2022111621A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4251613A4 (en) * | 2020-11-27 | 2024-11-20 | Allorion Therapeutics Inc. | AMINOHETEROARYL KINASE INHIBITORS |
| CA3207392A1 (en) * | 2021-02-05 | 2022-08-11 | Xiaoxia Yan | Cdk inhibitor |
| EP4532473A1 (en) * | 2022-05-27 | 2025-04-09 | Allorion Therapeutics Inc. | Aminoheteroaryl kinase inhibitors |
| WO2025006400A1 (en) * | 2023-06-25 | 2025-01-02 | Allorion Therapeutics Inc | Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| EP4725942A1 (en) * | 2024-10-09 | 2026-04-15 | Sibylla Biotech S.p.A. | Compounds active on cyclin d1 pathway and their use |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| BR0116452A (pt) * | 2000-12-21 | 2003-09-30 | Glaxo Group Ltd | Composto, composição farmacêutica, uso de um composto |
| BR0209774A (pt) * | 2001-05-29 | 2004-06-01 | Schering Ag | Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento |
| GB0113041D0 (en) * | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| IL161663A0 (en) * | 2001-11-01 | 2004-09-27 | Janssen Pharmaceutica Nv | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3beta INHIBITORS |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| EP1483260A1 (de) * | 2002-03-11 | 2004-12-08 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
| JP2006508997A (ja) * | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用 |
| US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| DE102005008310A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
| AU2006244195B2 (en) * | 2005-05-05 | 2012-03-15 | Ardea Biosciences, Inc. | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV |
| AU2007338792B2 (en) * | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| CN101679440A (zh) * | 2007-04-02 | 2010-03-24 | 帕劳制药股份有限公司 | 作为jak3抑制剂的吡咯并嘧啶衍生物 |
| WO2008128231A1 (en) * | 2007-04-16 | 2008-10-23 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
| CN101678215B (zh) * | 2007-04-18 | 2014-10-01 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
| WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| EP2179992A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| TW201024281A (en) * | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| US9145402B2 (en) * | 2011-11-29 | 2015-09-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
| NZ629830A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| CN110386901B (zh) * | 2018-04-23 | 2022-11-25 | 上海医药工业研究院 | 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用 |
| WO2019213340A1 (en) * | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
| WO2020205560A1 (en) * | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| EP4110782A1 (en) * | 2020-02-28 | 2023-01-04 | Fochon Biosciences, Ltd. | Compounds as cdk2/4/6 inhibitors |
| US20230411615A1 (en) * | 2020-11-04 | 2023-12-21 | Umicore | A positive electrode active material for rechargeable batteries |
| EP4251613A4 (en) * | 2020-11-27 | 2024-11-20 | Allorion Therapeutics Inc. | AMINOHETEROARYL KINASE INHIBITORS |
| CA3207392A1 (en) * | 2021-02-05 | 2022-08-11 | Xiaoxia Yan | Cdk inhibitor |
-
2021
- 2021-11-26 EP EP21897121.6A patent/EP4251613A4/en active Pending
- 2021-11-26 WO PCT/CN2021/133429 patent/WO2022111621A1/en not_active Ceased
- 2021-11-26 IL IL303237A patent/IL303237A/en unknown
- 2021-11-26 CA CA3202990A patent/CA3202990A1/en active Pending
- 2021-11-26 US US18/254,573 patent/US20240166635A1/en active Pending
- 2021-11-26 AU AU2021385745A patent/AU2021385745C1/en active Active
- 2021-11-26 KR KR1020237021724A patent/KR20230127228A/ko active Pending
- 2021-11-26 CN CN202180079929.6A patent/CN116528869B/zh active Active
- 2021-11-26 JP JP2023531615A patent/JP2024506116A/ja active Pending
-
2022
- 2022-11-23 AU AU2022397678A patent/AU2022397678A1/en active Pending
- 2022-11-23 CN CN202280077473.4A patent/CN118475562A/zh active Pending
- 2022-11-23 MX MX2024006300A patent/MX2024006300A/es unknown
- 2022-11-23 CA CA3238970A patent/CA3238970A1/en active Pending
- 2022-11-23 EP EP22897852.4A patent/EP4436959A4/en active Pending
- 2022-11-23 WO PCT/CN2022/133770 patent/WO2023093769A1/en not_active Ceased
- 2022-11-23 JP JP2024531423A patent/JP2024541533A/ja active Pending
-
2024
- 2024-05-21 US US18/670,469 patent/US20250002480A1/en active Pending
-
2025
- 2025-01-02 AU AU2025200001A patent/AU2025200001A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024506116A5 (https=) | ||
| JP2024513881A5 (https=) | ||
| JP2022533398A5 (https=) | ||
| JP2022538228A5 (https=) | ||
| JP2022538923A5 (https=) | ||
| JP2022547952A5 (https=) | ||
| JP2016053042A5 (https=) | ||
| RU2011102587A (ru) | Дизамещенные фенильные соединения | |
| RU2016120012A (ru) | Ингибиторы рецептора фактора роста фибробластов | |
| JP2007524696A5 (https=) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| JP2020521766A5 (https=) | ||
| CA2679232A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof | |
| JP2020533347A5 (https=) | ||
| JP2007517846A5 (https=) | ||
| JP2007538092A5 (https=) | ||
| JP2014503567A5 (https=) | ||
| JP2021500332A5 (https=) | ||
| RU2011124894A (ru) | Триазолотиадиазоловый ингибитор протеинкиназы с-мет | |
| RU98117621A (ru) | Новые производные пиперазина и пиперидина, способ их получения, фармкомпозиция на их основе, способ лечения, промежуточный продукт | |
| PE20241934A1 (es) | Inhibidores de raf quinasa y metodos de uso de los mismos | |
| JP2020502116A5 (https=) | ||
| AR046967A1 (es) | Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |